NCT01783197View on ClinicalTrials.gov

Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 4, 2013

Primary Completion Date

April 18, 2017

Study Completion Date

April 2, 2019

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Paclitaxel

DRUG

Carboplatin

DRUG

Selumetinib

DRUG

Pemetrexed

DRUG

Cisplatin

Trial Locations (4)

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K7L 5P9

Cancer Centre of Southeastern Ontario at Kingston, Kingston

K1H 8L6

Ottawa Hospital Research Institute, Ottawa

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Canadian Cancer Trials Group

NETWORK

NCT01783197 - Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC | Biotech Hunter | Biotech Hunter